Effect of Ivacaftor in patients with cystic fibrosis, and a G551D-CFTR mutation: expanded acces program in the United States
Taylor-Cousar JL, Nikknian M, Gilmartin G and Pilewski J, J Cyst Fibros, 1/11/2015Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis
Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW; GOAL Investigators of th..., Am J Respir Crit Care Med, 1/15/2014Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)
McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC; VX08-770-105 (PE..., Lancet Respir Med, 1/1/2014
